$1,318.00
This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals.
This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition de
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Disease definition
7 Patient subtypes
8 Symptoms
8 Risk factors
8 Diagnosis
9 TREATMENT
9 Anti-TB drugs
10 Surgery
11 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
24 KEY UPCOMING EVENTS
25 KEY REGULATORY EVENTS
25 CHMP Recommends Approval Of Extended Indication For Deltyba
26 PROBABILITY OF SUCCESS
27 LICENSING AND ASSET ACQUISITION DEALS
27 Patent Pool Welcomes Long-Acting Injectables License
27 Lupin Strikes Deal For Anti-TB Drug Pretomanid
28 CLINICAL TRIAL LANDSCAPE
29 Sponsors by status
30 Sponsors by phase
31 Recent events
32 BIBLIOGRAPHY
33 APPENDIX
LIST OF FIGURES
13 Figure 1: Global trends in incident cases of tuberculosis, 2020–29
19 Figure 2: Overview of pipeline drugs for tuberculosis in the US
19 Figure 3: Pipeline drugs for tuberculosis, by company
20 Figure 4: Pipeline drugs for tuberculosis, by drug type
20 Figure 5: Pipeline drugs for tuberculosis, by classification
24 Figure 6: Key upcoming events in tuberculosis
26 Figure 7: Probability of success in the antibacterial, mycobacterial, or fungal pipeline
28 Figure 8: Clinical trials in tuberculosis
28 Figure 9: Top 10 drugs for clinical trials in tuberculosis
29 Figure 10: Top 10 companies for clinical trials in tuberculosis
29 Figure 11: Trial locations in tuberculosis
30 Figure 12: Tuberculosis trials status
31 Figure 13: Tuberculosis trials sponsors, by phase
LIST OF TABLES
12 Table 1: Global incident cases of tuberculosis, 2020–29
14 Table 2: Incident cases of tuberculosis and HIV co-infection, 2020
15 Table 3: Incident cases of MDR/RR tuberculosis, 2020
17 Table 4: Marketed drugs for tuberculosis
21 Table 5: Pipeline drugs for tuberculosis in the US
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!